
strong result updat disclosur around nexsi de-
risk overweight thesi see guidanc
conserv impli deceler nexsi roll-out
reiter overweight pt
strong start year report revenu
vs mse reflect organ growth versu estim plasma
growth particular materi posit surpris versu
estim discuss hemostasi growth encourag
driven teg oper margin bp above-
consensu expect driven primarili gross margin upsid
includ bp fx benefit sg disciplin ep vs mse
materi expect pleas see exhibit reconcili
plasma thesi de-risk number look conserv haemonet
disclos sign sever long-term nexsi nexlynk contract
begun roll-out place devic date custom
feedback manag confid abil replac
nexsi system remain strong contract execut primari
risk nexsi thesi commentari quarter de-risk
pertain guidanc plasma growth north america
quarter maintain plasma guidanc impli mid high-singl
digit growth subsequ quarter seem conserv us reason
custom order time flag primari reason higher
plasma growth quarter reflect bulk ahead
nexsi launch expect impact nexsi
price benefit nexsi provid
materi lift subsequ quarter growth rate think like
get updat nexsi placements/convers given
placement start earlier expect could pull
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
adjust rang expect price benefit annual guidanc look
suggest underli growth rate market plasma
remaind year think unlik given tight plasma
conclus reason believ contract term differ
materi assumpt set forth upgrad recent dilig
deceler contract unlik guidanc like conserv
hold top-line guidanc constant currenc cc organ
growth impli averag growth remain quarter
high end given similar averag quarterli comp throughout
suggest underli pt momentum deceler note
manag team histor rais guidanc
like prudent earli year find difficult see
slowdown upcom nexsi traction instead model closer cc
growth year margin expect similar level quarter
rather step materi last two
year cost initi save help off-set nexsi depreci
invest recent execut leav us comfort upper half
guidanc even account higher interest expens ep
estim move top end manag guidanc rang
ultim view maintain guidanc light strong perform
reiter overweight pt overweight haemonet see
visibl path exceed lrp given nexsi price power
complex reduct initi disclosur quarter compani
enter long-term contract began nexsys/nexlynk roll-out
sever plasma custom de-risk first compon thesi margin
execut leav us comfort second previous valu
haemonet discount smid cap peer execut risk
given updat think in-lin multipl appropri profit
smid cap med-tech exhibit current trade ev/ebitda
rais price target reflect ebitda estim
remain overweight
haemonet nexsi drive transform stori
haemonet nexsi drive transform stori
price target reflect ev/ebitda
estim line smid cap peer
upsid nexsi price complex reduct initi dropthrough
balanc sheet option drive ebit achiev
per liter increment plasma price nexsi greater cost
save drop balanc sheet option third parti financ
capit deploy drive materi upsid ebit
nexsi complex reduct initi drive ebit
haemonet abl achiev per liter increment plasma price
nexsi save help compani exceed lrp ebit object
nexsi unabl gain materi price benefit nexsi unabl
creat materi valu custom and/or unabl obtain
competit price plasma growth remain line market growth rate
minim cost save drop
stori tie long-
rang plan lrp doubl oper incom
quadrupl turnaround
primarili lever nexsi product
compani next-gener plasma
valu creation materi yield
opportun appreci see
posit backdrop nexsi drive
valu per liter plasma
custom expect share
profit increment per
liter price indic nexsi alon
drive lrp object
complex reduct initi
seek provid cost save
add option de-risk
lrp believ allow haemonet
exceed lrp object
nexsi valu price potenti
drop-through
risk achiev price
benefit nexsi ii identif
addit cost opportun iii capit
downsid risk includ nexsi
disappoint ii cost save fail materi
iii blood bank slow materi iv
million except ep
sale
sale
sale
sale
sale
sale
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
equival
accum comprehens incom
dollar million except per share data
loss asset dispos
chang work capit
net provid oper activ
capit intang asset
sale properti invest
net use invest activ
chang equiti
net financ activ
net chang
equival bop
equival eop
